META FINES
Latest round
- Series B
Last raised
- Apr 2022
Total raised
- $24M
Investors
- 10
About META FINES
Based in South Korea, and founded in 2018, META FINES, INC. operates as a developer of a low-toxic anticancer drug. In April 2022, META FINES, INC. The company offers ASCA101, which is a drug development technology that develops low-toxic anticancer drugs for cancer treatments including intractable and terminal cancers. In addition, the company also offers anticancer palliative drugs, including cancer cachexia.
Who invested in META FINES
10 investors across 2 rounds
See all investors in META FINES
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about META FINES
Who invested in META FINES?
META FINES has 10 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has META FINES raised?
META FINES has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did META FINES last raise money?
META FINES's most recent round on record is a Series B, in Apr 2022.
What does META FINES do?
Based in South Korea, and founded in 2018, META FINES, INC.
Where is META FINES headquartered?
META FINES is headquartered in Seongnam, South Korea.
Which VCs invest in companies like META FINES?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at META FINES's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like META FINES? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.